Registration by the California Department of Food and Agriculture also carries the Organic Input Material (OIM) Program certification for use in organic crop and food production.
Inocucor has hired agriculture-industry veteran Bill Schwoerer to lead its California market rollout as Sales Manager for California. Schwoerer has spent most of his professional career working in agriculture, most recently as Biorational Sales Specialist for Valent USA, and earlier in sales and sales management positions at Abbott Laboratories Agricultural Chemicals, Seminis, Inc. and Harris Moran Seed Company.
"Many start-ups and emerging companies in the microbial products arena are still in R & D mode. Our product development and formulation scientists have produced a commercially proven, patented first-in-class bio-stimulant product that is available for California's high-value produce growers today," said Donald R. Marvin, president and CEO of Inocucor. "We anticipate Inocucor will gain rapid acceptance from California's vast network of innovative, production-minded farmers, large and small, organic and conventional."
Marvin said Inocucor is already in discussions with California's leading agricultural product distributors and is currently in large-scale field trials with a cadre of the state's leading strawberry, tomato, lettuce and broccoli growers.
Garden Solution, which is OMRI Listed for organic production, has previously been approved by regulators in 22 U.S. states, and is in use by greenhouse growers and farmers in the Carolinas, Florida, Georgia and Virginia.
Inocucor's second-generation sustainable biological accelerator Synergro-Free is targeted at production agriculture row crops. Recent field trials of Synergro-Free with industry partners have produced significant yield increases documented by third parties. Synergro-Free is currently approved in 16 U.S. states.
Last November, Inocucor was issued patent No. 9,175,258 by the U.S. Patent and Trademark Office to protect Inocucor consortia and unique microbial products. The company is currently completing a Series B equity-financing round on the order of $8 to $10 million with venture capital, institutional and family office investors. Funds will be used to scale-up its commercialization activities in North America.
For more information
Inocucor